US paus­es dis­tri­b­u­tion of Lil­ly mAb com­bo to Mass­a­chu­setts due to Covid-19 vari­ant

Now that the CDC has found that the Covid-19 vari­ant orig­i­nal­ly iden­ti­fied in Brazil is cir­cu­lat­ing with a fre­quen­cy ex­ceed­ing 10% in Mass­a­chu­setts, the US has halt­ed ship­ments of Eli Lil­ly’s mon­o­clon­al an­ti­body com­bo treat­ment be­cause it’s not ac­tive against this vari­ant.

The FDA rec­om­mends that health care providers in Mass­a­chu­setts use Re­gen­eron’s mon­o­clon­al an­ti­body as an al­ter­na­tive to Lil­ly’s ther­a­py un­til fur­ther no­tice.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER